Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 14/20 | 1.00 |
| ▸ | ACE | P12821 | 7/20 | 1.00 |
| ▸ | MMEL1 | Q495T6 | 3/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lbq-657 SCHEMBL9565416 | 1.00 | MME (1.00) | MMEACEMMEL1 | |
| Lbq-657 SCHEMBL1908575 | 1.00 | MME (1.00) | MMEACEMMEL1 | |
| Lbq-657 SCHEMBL489122 | 1.00 | MME (1.00) | MMEACEMMEL1 | |
| Lbq-657 SCHEMBL7433849 | 1.00 | MME (1.00) | MMEACEMMEL1 | |
| SCHEMBL9565424 | 0.93 | MME (0.86) | MMEACEMMEL1 | |
| SCHEMBL9565420 | 0.93 | MME (0.86) | MMEACEMMEL1 | |
| SCHEMBL7441588 | 0.91 | MME (0.84) | MMEACEMMEL1 | |
| SCHEMBL18396712 | 0.90 | MME (0.81) | MMEACEMMEL1 | |
| SCHEMBL9565409 | 0.90 | MME (0.81) | MMEACEMMEL1 | |
| SCHEMBL22556618 | 0.89 | MME (0.80) | MMEACEMMEL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 273 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240342188-A1 | Use of NEP Inhibitors for the Treatment of Laminitis | CURTAILS LLC (US) | 2024-10-17 | — | — | US | claimed |
| US-20240342187-A1 | USE OF NEP INHIBITORS FOR THE TREATMENT OF GASTROINTESTINAL SPHINCTER DISORDERS | CURTAILS LLC (US) | 2024-10-17 | — | — | US | claimed |
| EP-3436047-B1 | DUAL ACE C-DOMAIN/NEP INHIBITORS | ANGIODESIGN UK LTD (GB) | 2024-04-24 | — | — | EP | claimed |
| CN-115144505-B | Method for simultaneously measuring valsartan, sha Kuba yeast and metabolite concentration of valsartan and Sha Kuba yeast in human urine by UPLC-MS/MS method | 四川大学华西医院 | 2024-01-19 | — | — | CN | claimed |
| CN-117064847-A | Sustained release type LBQ657 hydrogel capable of treating fibrosis and preparation method thereof | 中国药科大学 | 2023-11-17 | — | — | CN | claimed |
| EP-3325013-B2 | STIMULATORS / ACTIVATORS OF SOLUBLE GUANYLAT CYCLASE IN COMBINATION WITH A NEP-INHIBITOR AND AN ANGIOTENSIN AII-ANTAGONIST AND THE USE THEREOF | Bayer Pharma AG (DE) | 2023-07-19 | — | — | EP | claimed |
| US-20230128032-A1 | Early Drug Interventions to Reduce COVID-19 Related Respiratory Distress, Need for Respirator Assist and Death | CURTAILS LLC (US) | 2023-04-27 | — | — | US | claimed |
| WO-2023018795-A1 | NEP INHIBITORS FOR THE TREATMENT OF LAMINITIS | CURTAILS LLC (US) | 2023-02-16 | — | — | WO | claimed |
| WO-2022265984-A1 | USE OF NEP INHIBITORS FOR THE TREATMENT OF GASTROINTESTINAL SPHINCTER DISORDERS | CURTAILS LLC (US) | 2022-12-22 | — | — | WO | claimed |
| CN-115389650-A | Method for simultaneously determining concentrations of valsartan, sha Kuba koji and metabolites thereof in human plasma by UPLC-MS/MS method | 四川大学华西医院 | 2022-11-25 | — | — | CN | claimed |
| EP-1948158-B1 | PHARMACEUTICAL COMBINATIONS OF AN ANGIOTENSIN RECEPTOR ANTAGONIST AND AN NEP INHIBITOR | NOVARTIS AG (CH) | 2014-01-29 | — | — | EP | claimed |
| EP-2608784-A1 | TREATMENT OF HYPERTENSION AND/OR PREVENTION OR TREATMENT OF HEART FAILURE IN A MAMMAL RECEIVING ANTI-COAGULANT THERAPY | Novartis AG (CH) | 2013-07-03 | — | — | EP | claimed |
| US-20130158086-A1 | METHODS OF TREATMENT AND PHARMACEUTICAL COMPOSITION | NOVARTIS AG (CH) | 2013-06-20 | — | — | US | claimed |
| US-20130158085-A1 | METHODS OF TREATMENT AND PHARMACEUTICAL COMPOSITION | NOVARTIS AG (CH) | 2013-06-20 | — | — | US | claimed |
| US-20130158088-A1 | TREATMENT OF HYPERTENSION AND/OR PREVENTION OR TREATMENT OF HEART FAILURE IN A MAMMAL RECEIVING ANTI-COAGULANT THERAPY | NOVARTIS AG (CH) | 2013-06-20 | — | — | US | claimed |
| US-8404744-B2 | Methods of treatment and pharmaceutical composition | NOVARTIS AG (CH) | 2013-03-26 | — | — | US | claimed |
| WO-2012027237-A1 | TREATMENT OF HYPERTENSION AND/OR PREVENTION OR TREATMENT OF HEART FAILURE IN A MAMMAL RECEIVING ANTI-COAGULANT THERAPY | NOVARTIS AG (CH) | 2012-03-01 | — | — | WO | claimed |
| US-8101659-B2 | Methods of treatment and pharmaceutical composition | NOVARTIS AG (CH) | 2012-01-24 | — | — | US | claimed |
| US-7468390-B2 | Angiotensin antagonist valsartan and an enkephalinase inhibitor; used to treat cardiovascular disorders | NOVARTIS AG (CH) | 2008-12-23 | — | — | US | claimed |
| EP-0555175-A1 | Biaryl substituted 4-amino-butyric acid amides | CIBA-GEIGY AG (CH) | 1993-08-11 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158086-A1 | METHODS OF TREATMENT AND PHARMACEUTICAL COMPOSITION | REN, AGTR1, TTR | MME 7/4885ACE 8/4885MMEL1 1432/4885 |
| US-20130158085-A1 | METHODS OF TREATMENT AND PHARMACEUTICAL COMPOSITION | REN, AGTR1, TTR | MME 7/4885ACE 8/4885MMEL1 1432/4885 |
| US-20240342188-A1 | Use of NEP Inhibitors for the Treatment of Laminitis | MME, REN, ACE | MME 1/4885ACE 3/4885MMEL1 218/4885 |
| US-20240342187-A1 | USE OF NEP INHIBITORS FOR THE TREATMENT OF GASTROINTESTINAL SPHINCTER DISORDERS | MME, REN, ACE | MME 1/4885ACE 3/4885MMEL1 266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.